Literature DB >> 20208569

The SFRP family of WNT inhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma.

P N Kongkham1, P A Northcott, S E Croul, C A Smith, M D Taylor, J T Rutka.   

Abstract

Medulloblastoma (MB) is the most common malignant pediatric brain tumor. Dysregulation of WNT signaling occurs in up to 20% of cases. Using a genome-wide approach, we identified the secreted frizzled-related protein 1, 2 and 3 (SFRP1, SFRP2 and SFRP3) family of WNT inhibitors as putative tumor suppressor genes silenced by promoter region methylation in MB. SFRP1, SFRP2 and SFRP3 expression increased after 5-aza-2'-deoxycytidine treatment. SFRP1, SFRP2 and SFRP3 methylation was identified in 23.5, 3.9 and 15.7% of primary MB specimens, respectively, by methylation-specific PCR. Stable SFRP1, SFRP2 and SFRP3 expression reduced phospho-DVL2 levels and hindered MB cell proliferation and colony formation in soft agar in vitro. In 60% of primary tumors, SFRP1 was expressed at levels twofold lower than that in normal cerebellum. SFRP1 expression impaired tumor formation in vivo in flank and orthotopic intracerebellar xenograft models and conferred a significant survival advantage (P<0.0001). We identify for the first time tumor suppressor gene function of SFRP genes in MB, and suggest that loss of WNT pathway inhibition due to SFRP gene silencing is an additional mechanism that may contribute to excessive WNT signaling in this disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20208569     DOI: 10.1038/onc.2010.32

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  50 in total

1.  [Expression of secreted frizzled-related protein 4 in DNA mismatch repair-deficient and mismatch repair-proficient colorectal cancers].

Authors:  Kexu Chen; Hanlin Liang; Jiewen Peng; Yanfang Zheng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-11-30

Review 2.  Wnt/beta-catenin signaling in glioma.

Authors:  Kailiang Zhang; Junxia Zhang; Lei Han; Peiyu Pu; Chunsheng Kang
Journal:  J Neuroimmune Pharmacol       Date:  2012-03-28       Impact factor: 4.147

Review 3.  Development and cancer of the cerebellum.

Authors:  Mary E Hatten; Martine F Roussel
Journal:  Trends Neurosci       Date:  2011-03       Impact factor: 13.837

4.  Genomic imbalances in esophageal carcinoma cell lines involve Wnt pathway genes.

Authors:  Jacqueline Brown; Hannelie Bothma; Robin Veale; Pascale Willem
Journal:  World J Gastroenterol       Date:  2011-06-28       Impact factor: 5.742

Review 5.  Wnt signaling in cancer.

Authors:  Paul Polakis
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-05-01       Impact factor: 10.005

6.  Secreted Frizzled-related protein 2 as a target in antifibrotic therapeutic intervention.

Authors:  Michalis Mastri; Zaeem Shah; Karin Hsieh; Xiaowen Wang; Bailey Wooldridge; Sean Martin; Gen Suzuki; Techung Lee
Journal:  Am J Physiol Cell Physiol       Date:  2013-12-11       Impact factor: 4.249

Review 7.  Wnt signaling in cardiovascular disease: opportunities and challenges.

Authors:  Austin Gay; Dwight A Towler
Journal:  Curr Opin Lipidol       Date:  2017-10       Impact factor: 4.776

Review 8.  Medulloblastoma development: tumor biology informs treatment decisions.

Authors:  Vidya Gopalakrishnan; Rong-Hua Tao; Tara Dobson; William Brugmann; Soumen Khatua
Journal:  CNS Oncol       Date:  2015

9.  Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.

Authors:  Martin Schlensog; Lara Magnus; Timon Heide; Julian Eschenbruch; Florian Steib; Maximilian Tator; Vera Kloten; Michael Rose; Erik Noetzel; Nadine T Gaisa; Ruth Knüchel; Edgar Dahl
Journal:  Epigenetics       Date:  2018-04-18       Impact factor: 4.528

10.  Transcriptome, methylome and genomic variations analysis of ectopic thyroid glands.

Authors:  Rasha Abu-Khudir; Jean Paquette; Anne Lefort; Frederick Libert; Jean-Pierre Chanoine; Gilbert Vassart; Johnny Deladoëy
Journal:  PLoS One       Date:  2010-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.